Patents Examined by Janet L Coppins
  • Patent number: 11478476
    Abstract: The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: October 25, 2022
    Assignee: CONTERA PHARMA APS
    Inventors: John Bondo Hansen, Mikael S. Thomsen
  • Patent number: 11478464
    Abstract: A method of treating inflammation includes administering an anti-inflammatory agent to a patient in need thereof. The anti-inflammatory agent is selected from Compound 1 ([(2-{[3-(4-methyl-1H-benzimidazol-2-yl)piperidin-1-yl]carbonyl}phenyl) amino] acetic acid) and Compound 2 (Ethyl-1-(5-cyano-2-hydroxyphenyl)-4-oxo-5-phenoxy-1,4-dihydropyridine-3-carboxylate). Compound 1 and Compound 2 selectively inhibit COX-2 enzyme, without substantially inhibiting COX-1 enzyme, in contrast to many other NSAIDs.
    Type: Grant
    Filed: February 6, 2022
    Date of Patent: October 25, 2022
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mahmoud Kandeel Elsayed, Shady Burayk
  • Patent number: 11446308
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 20, 2022
    Inventors: Jian Zuo, Tai Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
  • Patent number: 11446294
    Abstract: Disclosed herein are non-platinum-based (NPB) anti-cancer compounds useful for targeted chemotherapy, e.g., to generate anti-cancer effects for the treatment of cancer and other disorders while having no or minimal toxicity. The compounds have the general formula I: (I) wherein A represents an aromatic core; at least one of Ra and Rb is an electron transfer promoter as defined herein, e.g., NH2; and at least one of Rc is a leaving group as defined herein, e.g., halogen; and the remainder of the molecule is as defined herein. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the anti-cancer compounds are also disclosed.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: September 20, 2022
    Inventor: Qing-Bin Lu
  • Patent number: 11433068
    Abstract: This disclosure provides compositions and methods of treating cancer by inhibiting histone methyltransferases alone or in combination by synergistically inhibiting a histone demethylase, or a histone deacetylase (HDAC), or a bromodomain (BRD)-containing protein, or a B-Raf kinase. In particular, the cancers have deficient of SWI/SNF chromatin remodeling complexes because of mutations in one or more of the complex's subunit members.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: September 6, 2022
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: David E. Fisher, Qing Yu Weng, Shinichiro Kato
  • Patent number: 11433055
    Abstract: The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 6, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Tesfaye Biftu, Xianhai Huang, Weiguo Liu, Weidong Pan, Min Park, Alexander Pasternak, Wanying Sun, Haifeng Tang, Yi Zang
  • Patent number: 11426360
    Abstract: Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of a natural pimarane diterpenoid extract of Hymenocrater elegans, or a derivative, analogue, or homolog thereof. Compounds based upon this natural extract have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: August 30, 2022
    Assignees: University of South Carolina, TIGHitco, Inc.
    Inventors: Ehsan Jabbarzadeh, Sara Eslambolchimoghadam
  • Patent number: 11426406
    Abstract: Provided herein are methods of treating a lysosomal storage disorder (LSD) in a subject and methods of promoting lysosomal clearance in one or more cells of a subject.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: August 30, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventor: Charbel Moussa
  • Patent number: 11413266
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 16, 2022
    Assignee: GW Pharma Limited
    Inventors: Tamás Biró, Colin Stott, Vincenzo Di Marzo
  • Patent number: 11406664
    Abstract: The use of ferric maltol compositions for the treatment or prevention of cancer and tumours is disclosed, in particular for the treatment or prevention of gastrointestinal cancers or gastrointestinal tumours, such as large bowel (colorectal), small bowel or upper gastrointestinal cancers.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: August 9, 2022
    Assignee: SHIELD TX (UK) LIMITED
    Inventors: Jonathan Joseph Powell, Dora I. A. Pereira
  • Patent number: 11399540
    Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: August 2, 2022
    Assignee: CORTEVA AGRISCIENCE LLC
    Inventors: Natalie C Giampietro, Jeffery D Webster, David A Demeter, Thomas C Sparks
  • Patent number: 11376242
    Abstract: Provided are methods and compositions for identifying candidate agents for treatment of obesity, liver disease, and/or diabetes. Such methods include, e.g., contacting a mammalian cell or cell population with a test agent, and measuring an expression level and/or activity level of ClpP in the mammalian cell or in cells of the cell population. Also provided are methods and compositions for treating an individual (e.g., one who is obese and/or has diabetes). Treatment methods include administering an inhibitor of ClpP to the individual (e.g., to prevent or reduce weight gain, to increase insulin sensitivity, and/or to increase glucose tolerance).
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: July 5, 2022
    Assignee: The J. David Gladstone Institutes
    Inventors: Yadong Huang, Qin Xu, Robert W. Mahley
  • Patent number: 11376228
    Abstract: A polysubstituted benzene compound, preparation method thereof, and method of using the same. The compound has a formula I or I?, where X represents carbon, sulfur, or oxygen; R1 represents a C1-16 alkyl, C2-16 alkenyl, or C2-10 alkynyl; R2 represents hydrogen, halogen, C1-16 alkyl, C2-16 alkenyl, or C2-10 alkynyl; or an aryl group or a substituted aryl group by 1-5 groups selected from halogen, C1-26 alkyl, C1-3 halogenated alkyl, O—C1-3 alkyl, hydroxyl, amino, nitro, cyano group, aldehyde group and ester group; or a heteroaryl group or a substituted heteroaryl group by 1-5 groups selected from halogen, C1-26 alkyl, C1-3 halogenated alkyl, O—C1-3 alkyl, hydroxyl, amino, nitro, cyano group, aldehyde group and ester group; the heteroaryl group is a 3-10-membered heteroaryl group including N, S, O, or a combination thereof.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: July 5, 2022
    Assignees: GENIFARM LABORATORIES INC, SOUTH CHINA UNIVERSITY OF TECHNOLOGY
    Inventors: Shifa Zhu, Tongxiang Cao, Yongdong Wang, Zhipeng Huang
  • Patent number: 11357739
    Abstract: Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment, as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of a natural pimarane diterpenoid extract of Hymenocrater elegans, or a derivative, analogue, or homolog thereof. Compounds based upon this natural extract have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: June 14, 2022
    Assignee: University of South Carolina
    Inventors: Ehsan Jabbarzadeh, Sara Eslambolchimoghadam
  • Patent number: 11344525
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 31, 2022
    Assignee: University of Mississippi
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11344510
    Abstract: Provided herein are arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: May 31, 2022
    Assignee: Gilgamesh Pharmaceuticals, Inc.
    Inventor: Andrew Carry Kruegel
  • Patent number: 11344555
    Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: May 31, 2022
    Assignee: The Regents of the University of California
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Patent number: 11337951
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 24, 2022
    Assignee: University of Mississippi
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11337952
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 24, 2022
    Assignee: University of Mississippi
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11337982
    Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: May 24, 2022
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Lue Dai, Lu Gao